In combination with anti‐PD‐L1 antibody, the nanomedicine was able to neutralize immunosuppressed glioma microenvironment and thus unleash antiglioma immune response, thereby efficiently reducing tumor recurrence. This evidence concerns the gene CD274 and neoplasm.